高危前列腺癌长期ADT联合高剂量放疗:GETUG AFU 18随机III期试验
GETUG AFU 18研究纳入505例高危前列腺癌患者,随机接受80 Gy或70 Gy放疗联合长期ADT。两组急性和晚期毒性相似,无治疗相关死亡。
要点
- 80 Gy剂量递增放疗联合长期ADT显著改善高危前列腺癌10年无进展生存。
- 5年无进展生存率两组接近,剂量递增获益主要体现在长期随访。
- 急性和晚期≥3级毒性两组相似,安全性可接受。
核心结论
- 高危前列腺癌患者接受80 Gy放疗联合长期ADT可改善无进展生存,可能成为治疗选择。
- 鉴于事件数较少,需进一步研究确认对前列腺癌特异生存和总生存的获益。
研究设计与样本
- 多中心、开放标签、随机III期试验,纳入法国25个中心的高危前列腺癌患者。
- 高危定义:PSA≥20 ng/mL,或Gleason评分≥8,或临床分期T3-T4。
- 共505例患者随机1:1分配至80 Gy组(250例)或70 Gy组(255例),均联合长期ADT。
- 主要终点为5年无进展生存,预设需197个事件,在意向治疗人群中分析。
主要发现
- 6个月时≥3级急性不良事件:80 Gy组60例(24%)vs 70 Gy组62例(25%)。
- 5年时晚期不良事件:80 Gy组118/168例(70%)vs 70 Gy组122/168例(73%);≥3级晚期毒性分别为19例(8%)vs 17例(7%)。
- 严重不良事件两组各9例(4%),均与治疗无关;无治疗相关死亡。
关键数值与推荐
- 剂量递增方案:80 Gy,2 Gy/次,共8周;标准剂量:70 Gy,2 Gy/次,共7周,均联合长期ADT。
- 生化进展定义:PSA>最低值+2 ng/mL;临床进展包括局部、区域或转移性进展。
临床怎么用
- 对于高危前列腺癌患者,可考虑80 Gy剂量递增放疗联合长期ADT以改善长期无进展生存。
- 治疗决策时需权衡剂量递增的长期获益与相似的不良事件风险。
局限性
- 5年事件数较少,10年无进展生存为事后分析。
- 开放标签设计,未设盲。
- 总生存和前列腺癌特异生存获益尚未证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with high-risk prostate cancer, the role of dose-escalated radiotherapy in combination with long-term androgen deprivation treatment (ADT) is controversial, without any demonstrated benefit on cancer-specific or overall survival. We aimed to evaluate the effect of a 10 Gy dose increase, from 70 Gy to 80 Gy, on progression-free survival in men with high-risk prostate cancer. METHODS: In this multicentre, open-label, randomised, phase 3 trial, we enrolled patients with high-risk prostate cancer, defined as prostate-specific antigen of 20 ng/mL or more, Gleason score of at least 8, or clinical stage T3-T4, from 25 centres in France. Participants were randomly assigned (1:1) by minimisation, stratified by centre and previous pelvic lymph node dissection, to receive prostate-targeted dose-escalated external beam radiotherapy (80 Gy; 2 Gy per fraction for 8 weeks) or standard-dose external beam radiotherapy (70 Gy; 2 Gy per fraction for 7 weeks), combined with long-term ADT. Neither the participants nor the investigators were masked to the allocated treatment. The primary endpoint was 5-year progression-free survival defined as the time from randomisation to first biochemical (defined as prostate-specific antigen >nadir plus 2 ng/mL) or clinical (ie, local, regional, or metastatic) disease progression, analysed in the intention-to-treat population, with 197 events required. 5-year progression-free survival was the prespecified endpoint, and 10-year progression-free survival was additionally reported (post hoc) in view of the low number of events at 5 years. The trial is registered at ClinicalTrials.gov, NCT00967863, and is complete. FINDINGS: Between April 6, 2009, and Jan 24, 2013, 505 patients with high-risk prostate cancer were enrolled; 250 were assigned to receive dose-escalated radiotherapy (80 Gy) and 255 to receive standard dose radiotherapy (70 Gy). All participants were male and ethnicity data were not collected. At a median follow-up of 9·5 years (IQR 8·5-10·3), 5-year progression-free survival was 91·4% (95% CI 87·0-94·4) in the dose-escalation group versus 88·1% (83·2-91·6) in the control group, and 10-year progression-free survival was 83·6% (77·8-88·0) versus 72·2% (65·3-78·0; stratified HR 0·56, 95% CI 0·40-0·78, p<0·0001). Grade 3 or worse adverse events assessed at 6 months (acute toxicity) were observed in 60 (24%) of patients in the dose-escalation group and 62 (25%) in the control group. The most frequent grade 3 or worse adverse events were sexual disorders (28 [11%] in the dose-escalation group vs 20 [8%] in the control group) and bladder or urethra disorders (12 [5%] vs 19 [8%]). Adverse events assessed at 5 years (late toxicity) occurred in 118 (70%) of 168 in the dose-escalation group and 122 (73%) of 168 in the control group; grade 3 or worse late toxicities occurred in 19 (8%) participants in the dose-escalated radiotherapy group versus 17 (7%) participants in the control group. The most common late grade 3 adverse event was bladder or urethra disorders (seven [4%] vs three [2%], respectively). Serious adverse events occurred in nine (4%) patients in the dose escalation group and nine (4%) in the control group; none were considered to be treatment related. There were no treatment-related deaths. INTERPRETATION: For patients with high-risk prostate cancer, radiotherapy at a total dose of 80 Gy, in combination with long-term ADT, improved progression-free survival and could be a potential option in this situation. However, given the low number of events, further research is needed to consolidate and confirm the benefit in dose-escalation in prostate cancer-specific survival and overall survival. FUNDING: French National Cancer Institute and AstraZeneca.
引用
- Hennequin C, Sargos P, Roca L, et al. High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial. Lancet Oncol. 2026. PMID: 42636837. doi:10.1016/S1470-2045(26)00277-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。